公开(公告)号：EP1572669A2

公开(公告)日：2005-09-14

申请号：EP03773584.2

申请日：2003-11-20

申请人： NOVO NORDISK A/S ,  Boehringer Ingelheim International GmbH

发明人： CONDE-FRIEBOES, Kilian, Waldemar ,  ANKERSEN, Michael ,  SENSFUSS, Ulrich ,  WULFF, Birgitte, Schjellerup ,  THOGERSEN, Henning ,  LUSTENBERGER, Philipp ,  RUDOLF, Klaus ,  KRIST, Bernd ,  MÜLLER, Stephan ,  STENKAMP, Dirk ,  SCHINDLER, Marcus ,  WIELAND, Heike ,  ARNDT, Kirsten

IPC分类号： C07D241/08 ,  C07D241/06 ,  A61K31/495 ,  A61P15/10

CPC分类号： C07D401/06 ,  C07D241/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D413/14

摘要： The present invention relates to novel compounds of the general formula (I) as well as any optical or geometric isomer or tautomer form thereof, or a pharmaceutically acceptable salt thereof, as agonists of melanocortin receptors, such as agonists of the MC4 receptor. The compounds may for instance be used in the treatment of obesity.

公开(公告)号：EP3946363A2

公开(公告)日：2022-02-09

申请号：EP20717107.5

申请日：2020-03-27

申请人： Novo Nordisk A/S

发明人： HOEG-JENSEN, Thomas ,  BEHRENS, Carsten ,  CLÓ, Emiliano ,  MÜNZEL, Martin, Werner, Borchsenius ,  SAUERBERG, Per ,  KRUSE, Thomas ,  SPETZLER, Jane ,  SENSFUSS, Ulrich ,  HJØRRINGGAARD, Claudia, Ulrich ,  THØGERSEN, Henning ,  BALSÁNEK, Vojtech ,  DROBNÁKOVÁ, Zuzana ,  DROZ, Ladislav ,  HAVRÁNEK, Miroslav ,  KOTEK, Vladislav ,  STENGL, Milan ,  SNAJDR, Ivan ,  VÁNOVÁ, Hana

IPC分类号： A61K31/69 ,  A61K47/54 ,  A61P3/10

公开(公告)号：EP2758426A1

公开(公告)日：2014-07-30

申请号：EP12759773.0

申请日：2012-09-21

申请人： Novo Nordisk A/S

发明人： LAU, Jesper, F. ,  KRUSE, Thomas ,  THØGERSEN, Henning ,  SENSFUSS, Ulrich ,  NIELSEN, Peter, Kresten

IPC分类号： C07K14/605 ,  A61K38/00

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/2278 ,  A61K38/26

摘要： The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

公开(公告)号：EP2448962A1

公开(公告)日：2012-05-09

申请号：EP10726515.9

申请日：2010-06-29

申请人： Novo Nordisk A/S

发明人： HOEG-JENSEN, Thomas ,  JAKOBSEN, Palle ,  SENSFUSS, Ulrich ,  FLEDELIUS, Christian ,  RIBEL-MADSEN, Ulla

IPC分类号： C07K14/62 ,  A61P3/10

CPC分类号： C07K14/62 ,  A61K38/00

摘要： The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.

公开(公告)号：EP2106406A2

公开(公告)日：2009-10-07

申请号：EP08707961.2

申请日：2008-01-17

申请人： Novo Nordisk A/S

发明人： SENSFUSS, Ulrich

IPC分类号： C07K14/68 ,  A61K38/34

CPC分类号： C07K14/68

摘要： The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

公开(公告)号：EP1809666A2

公开(公告)日：2007-07-25

申请号：EP05801398.8

申请日：2005-11-04

申请人： Novo Nordisk A/S

发明人： SENSFUSS, Ulrich ,  CHRISTENSEN, Leif ,  CONDE FRIEBOES, Kilian Waldemar ,  PETTERSSON, Ingrid

IPC分类号： C07K14/68

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K7/08

摘要： The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

摘要翻译： 本发明涉及有效调节一种或多种黑皮质素受体类型的新型肽化合物，涉及该化合物在治疗中的用途，涉及包括将该化合物给予有需要的患者的治疗方法，以及涉及 化合物在药物制造中的应用。 本发明化合物在治疗肥胖以及与肥胖有关的各种疾病或病症方面特别有意义。

公开(公告)号：EP3204408B1

公开(公告)日：2020-05-06

申请号：EP15778311.9

申请日：2015-10-09

申请人： Novo Nordisk A/S

发明人： REEDTZ-RUNGE, Steffen ,  SENSFUSS, Ulrich ,  KRUSE, Thomas ,  SPETZLER, Jane ,  THØGERSEN, Henning ,  WENZEL TORNØE, Christian ,  LAU, Jesper F.

IPC分类号： C07K14/605 ,  A61K38/26

公开(公告)号：EP2758426B1

公开(公告)日：2019-08-07

申请号：EP12759773.0

申请日：2012-09-21

申请人： Novo Nordisk A/S

发明人： LAU, Jesper, F. ,  KRUSE, Thomas ,  THØGERSEN, Henning ,  SENSFUSS, Ulrich ,  NIELSEN, Peter, Kresten

IPC分类号： C07K14/605 ,  A61K38/00

公开(公告)号：EP3151852A1

公开(公告)日：2017-04-12

申请号：EP15725074.7

申请日：2015-06-03

申请人： Novo Nordisk A/S

发明人： SENSFUSS, Ulrich ,  LAU, Jesper F. ,  KRUSE, Thomas

IPC分类号： A61K38/26 ,  C07K14/605 ,  A61K47/50

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/28 ,  A61K2300/00

摘要： The present invention relates to novel glucagon derivatives which are GLP-1/glucagon receptor co-agonists, and to the use of said glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.

摘要翻译： 本发明涉及GLP-1 /胰高血糖素受体共激动剂的新型胰高血糖素衍生物，以及所述胰高血糖素衍生物在医药中的用途，例如治疗糖尿病，肥胖症及相关疾病和病症。

公开(公告)号：EP2986313A1

公开(公告)日：2016-02-24

申请号：EP14719715.6

申请日：2014-04-22

申请人： Novo Nordisk A/S

发明人： SENSFUSS, Ulrich ,  KRUSE, Thomas ,  LAU, Jesper F.

IPC分类号： A61K38/26 ,  A61K47/48 ,  C07K14/605

CPC分类号： C07K14/605 ,  A61K38/26 ,  A61K38/28

摘要： The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.

摘要翻译： 本发明涉及新型稳定和延长的GLP-1 /胰高血糖素受体共激动剂，在治疗中使用所述肽，包括向患者施用所述肽的治疗方法，以及所述肽在制备中的用途 药物。